Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Markets end flat on weak global cues
Thu, 28 May Closing

The Indian equity markets closed below the dotted line in what was a volatile trading session today. The BSE Sensex closed lower by 58 points while NSE-Nifty closed lower by 15 points. BSE Mid Cap and BSE Small Cap indices also underperformed closing 0.5% and 0.2% lower respectively. Sectoral indices ended the day on a mixed note. Consumer Durables gained the most followed by IT sector stocks. However, Healthcare and Banking stocks witnessed majority of the selling activity.

Asian shares shed gains as the Chinese, Hong Kong and Singapore markets slipped. European markets are mixed to lower. Shares in France are off as the CAC 40 drops 0.56%. The DAX is down 0.35% while the FTSE 100 in London is unchanged. The rupee was trading strong by 17 paise at 63.84 in the afternoon session on heavy selling of dollar.

According to a leading financial daily, Vedanta India will acquire up to 5.33% stake, worth over Rs 22 bn in Cairn India next week. Vedanta India, which changed the name from Sesa Sterlite last month, is a promoter in Cairn India. Reportedly, it will acquire up to 100 million shares of the company from another promoter Twin Star Mauritius Holdings Ltd. After the acquisition of the shares, Vedanta India's stake in Cairn India will grow from 18.73% to 24.06%. Twin Star Mauritius Holdings held 39.41% stake in Cairn India as of March 2015. Shares of Cairn India ended the trading session up by 0.21% at Rs. 191 per share on the BSE. Vedanta India ended up by 2.34%.

According to a leading financial daily, drug-maker Cipla and vaccine maker Serum have entered into a joint venture for the second time to market flu vaccine Nasovac-S in India. As per the reports, Serum will develop and manufacture the vaccine, and Cipla will exclusively market it in India. The advantage of the Nasovac-S vaccine is that it is given through the nasal route, unlike vaccines that are injected in. Cipla does not possess any presence in the vaccination segment which makes this deal more lucrative for Cipla. The two companies have been in the news recently on speculation that they could merge.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Markets end flat on weak global cues". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.